EUROPE EARNINGS – 10 MAY 2012

Deutsche Telekom AG – Co.’s 1Q12 earnings came in better than expected results as European revenues declined lesser than expected and the performance of its US T-Mobile division was higher. EBITDA excl. items declined 0.1 percent to EUR 4.48 b (EUR 5.8 b) vs expectations of EUR 4.4 b. Revenues of the firm declined 1.1 percent to EUR 14.4 b.  Net profit came in at EUR 238 m vs EUR 480 a year ago. the co. is to give a dividend of 70 cents a share. (Bloomberg)

Telecom Italia SpA – Co. reported 1Q12 profits at EUR 606 m (USD 785 m ) vs expectations of EUR 572.3 m vs EUR 549 m a year ago on higher revenues from Brazilian and Argentine operations. Revenues rose 4.5 percent to EUR 7.39 b vs expectations of EUR 7.32 b.  EBITDA came in at EUR 30.3 b vs EUR 30.4 b a year ago.(Bloomberg)

British Telecom – Co. reported a 4Q11-12 net profit at GBP 632m vs. estimated GBP 552m vs. previous 4Q10-11 at GBP 472m. For FY11-12 operating profit at GBP 849m; revenue at GBP 4.8b. (CNBC/Nasdaq filing)

Capgemini – Co. reported 1Q12 consolidated revenue at EUR 2565m vs. estimated EUR 2464m vs. previous EUR 2350m. (MarketWatch)

Aegon – Co. reported 1Q12 net profit at EUR 521m vs. estimated EUR 276m. (Reuters)

GLENMARK PHARMA’S STOCK TRADES AT A 52-WEEK HIGH ON STRONGER FY13 GUIDANCE

Glemnark Pharma’s management has raised its FY13 guidance predicting stronger results. The stock price hit its 52 week high during trades on the estimates of revenues growing by 22-25 percent and EBITDA growth of 19-20 percent. The stock opened at INR 342 a share and touched a high of INR 360 on the news.

RANBAXY LABS 1Q12 PROFIT AT INR 12468 m vs prv INR 3044 m

Ranbaxy Laboratories – Co. reported 1Q12 consolidated sales at INR 37002m vs. previous 1Q11 at INR 21453m. EBITDA for 1Q12 at INR 10152m vs. previous 1Q11 at INR 4261m. PAT at INR 12468m vs. previous INR 3044m. (BSE Filing)

ANHEUSER BUSCH InBEV 1Q12 PROFIT AT USD 1.69 b vs. exp. USD 1.39 b vs prv. USD 964 m

Anheuser Busch InBev N.V- Co. reported 1Q12 net profit at USD 1.69b vs. expected USD 1.39b vs. previous USD 964m. Revenue at USD 9.33b vs. expected USD 9.35b vs. previous USD 9b. EBITDA at USD 3.55 b vs. expected USD 3.59b vs. previous 3.41b. (WSJ)